Research and Markets forecasts robust growth in the Artificial Intelligence in precision medicine market, projecting a rise from USD 1.03 billion in 2024 to USD 10.24 billion by 2032, at a CAGR of 33.18%. The report details how deep learning and machine learning facilitate precision diagnostics, drug development, and therapeutic personalization to address the global burden of chronic and genetic diseases across major regions.

Key points

• Deep learning and machine learning algorithms drive high-throughput analysis of genomic, proteomic, and clinical datasets.
• Tempus ECG-AF AI model achieves early atrial fibrillation detection with FDA clearance, exemplifying regulatory success.
• North America leads deployment with advanced R&D infrastructure, contributing to projected market value of USD 10.24 billion by 2032 (CAGR 33.18%).